| [1] |
BAGCHI S, YUAN R, ENGLEMAN EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annu Rev Pathol, 2021, 16: 223-249. DOI: 10.1146/annurev-pathol-042020-042741. |
| [2] |
KUMAR V, CHAUDHARY N, GARG M, et al. Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAE) induced by immune checkpoint inhibitor therapy[J]. Front Pharmacol, 2017, 8: 311. DOI: 10.3389/fphar.2017.00311. |
| [3] |
ZEN Y, YEH MM. Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy[J]. Semin Diagn Pathol, 2019, 36(6): 434-440. DOI: 10.1053/j.semdp.2019.07.009. |
| [4] |
XIAO J, WANG F, WONG NK, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective[J]. J Hepatol, 2019, 71(1): 212-221. DOI: 10.1016/j.jhep.2019.03.004. |
| [5] |
EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2. |
| [6] |
General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009. |
| [7] |
YAU T, HSU C, KIM TY, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis[J]. J Hepatol, 2019, 71(3): 543-552. DOI: 10.1016/j.jhep.2019.05.014. |
| [8] |
PU D, YIN L, ZHOU Y, et al. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review[J]. Medicine (Baltimore), 2020, 99(5): e19013. DOI: 10.1097/MD.0000000000019013. |
| [9] |
PAN S, YU Y, WANG S, et al. Correlation of HBV DNA and hepatitis B surface antigen levels with tumor response, liver function and immunological indicators in liver cancer patients with hbv infection undergoing PD-1 inhibition combinational therapy[J]. Front Immunol, 2022, 13: 892618. DOI: 10.3389/fimmu.2022.892618. |
| [10] |
NG K, WONG L, ANG A, et al. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center[J]. Asia Pac J Clin Oncol, 2021, 17(5): e249-e261. DOI: 10.1111/ajco.13454. |
| [11] |
ALKREKSHI A, TAMASKAR I. Safety of immune checkpoint inhibitors in patients with cancer and hepatitis C virus infection[J]. Oncologist, 2021, 26(5): e827-e830. DOI: 10.1002/onco.13739. |
| [12] |
SHAH NJ, AL-SHBOOL G, BLACKBURN M, et al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection[J]. J Immunother Cancer, 2019, 7(1): 353. DOI: 10.1186/s40425-019-0771-1. |
| [13] |
BRAHMER J, RECKAMP KL, BAAS P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2): 123-135. DOI: 10.1056/NEJMoa1504627. |
| [14] |
BORGHAEI H, PAZ-ARES L, HORN L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639. DOI: 10.1056/NEJMoa1507643. |
| [15] |
XU F, ZENG Z, YAN B, et al. Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study[J]. Transl Lung Cancer Res, 2021, 10(4): 1819-1828. DOI: 10.21037/tlcr-21-79. |
| [16] |
PERTEJO-FERNANDEZ A, RICCIUTI B, HAMMOND SP, et al. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection[J]. Lung Cancer, 2020, 145: 181-185. DOI: 10.1016/j.lungcan.2020.02.013. |
| [17] |
HODI FS, O'DAY SJ, MCDERMOTT DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010, 363(8): 711-723. DOI: 10.1056/NEJMoa1003466. |
| [18] |
RAVI S, SPENCER K, RUISI M, et al. Ipilimumab administration for advanced melanoma in patients with pre-existing hepatitis B or C infection: a multicenter, retrospective case series[J]. J Immunother Cancer, 2014, 2(1): 33. DOI: 10.1186/s40425-014-0033-1. |
| [19] |
WEN X, WANG Y, DING Y, et al. Safety of immune checkpoint inhibitors in Chinese patients with melanoma[J]. Melanoma Res, 2016, 26(3): 284-289. DOI: 10.1097/CMR.0000000000000256. |
| [20] |
LEE PC, CHAO Y, CHEN MH, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(2). DOI: 10.1136/jitc-2020-001072. |
| [21] |
ZHANG X, ZHOU Y, CHEN C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition[J]. J Immunother Cancer, 2019, 7(1): 322. DOI: 10.1186/s40425-019-0808-5. |
| [22] |
YOO S, LEE D, SHIM JH, et al. Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment[J]. Clin Gastroenterol Hepatol, 2022, 20(4): 898-907. DOI: 10.1016/j.cgh.2021.06.019. |
| [23] |
DING ZN, MENG GX, XUE JS, et al. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis[J]. J Cancer Res Clin Oncol, 2022. DOI: 10.1007/s00432-022-04133-8. |
| [24] |
IOANNOU GN. Epidemiology and risk-stratification of NAFLD-associated HCC[J]. J Hepatol, 2021, 75(6): 1476-1484. DOI: 10.1016/j.jhep.2021.08.012. |
| [25] |
DE OLIVEIRA S, HOUSERIGHT RA, GRAVES AL, et al. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish[J]. J Hepatol, 2019, 70(4): 710-721. DOI: 10.1016/j.jhep.2018.11.034. |
| [26] |
PFISTER D, NU'ÑEZ NG, PINYOL R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC[J]. Nature, 2021, 592(7854): 450-456. DOI: 10.1038/s41586-021-03362-0. |
| [27] |
KICHENADASSE G, MINERS JO, MANGONI AA, et al. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer[J]. JAMA Oncol, 2020, 6(4): 512-518. DOI: 10.1001/jamaoncol.2019.5241. |
| [28] |
CORTELLINI A, BERSANELLI M, BUTI S, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable[J]. J Immunother Cancer, 2019, 7(1): 57. DOI: 10.1186/s40425-019-0527-y. |
| [29] |
WANG Z, AGUILAR EG, LUNA JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade[J]. Nat Med, 2019, 25(1): 141-151. DOI: 10.1038/s41591-018-0221-5. |
| [30] |
ZHOU J, ZHOU F, CHU X, et al. Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases[J]. Transl Lung Cancer Res, 2020, 9(2): 316-324. DOI: 10.21037/tlcr.2020.04.15. |
| [31] |
BESSONE F, DIRCHWOLF M, RODIL MA, et al. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view[J]. Aliment Pharmacol Ther, 2018, 48(9): 892-913. DOI: 10.1111/apt.14952. |
| [32] |
SAWADA K, HAYASHI H, NAKAJIMA S, et al. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor[J]. J Gastroenterol Hepatol, 2020, 35(6): 1042-1048. DOI: 10.1111/jgh.14889. |
| [33] |
ZHANG X, YANG H, ZENG S, et al. Melanoma differentiation-associated gene 5 protects against NASH in mice[J]. Hepatology, 2022, 75(4): 924-938. DOI: 10.1002/hep.32139. |
| [34] |
MCQUADE JL, DANIEL CR, HESS KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis[J]. Lancet Oncol, 2018, 19(3): 310-322. DOI: 10.1016/S1470-2045(18)30078-0. |
| [35] |
DE MARTIN E, MICHOT JM, PAPOUIN B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors[J]. J Hepatol, 2018, 68(6): 1181-1190. DOI: 10.1016/j.jhep.2018.01.033. |
| [36] |
MENZIES AM, JOHNSON DB, RAMANUJAM S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab[J]. Ann Oncol, 2017, 28(2): 368-376. DOI: 10.1093/annonc/mdw443. |
| [37] |
BHAVE P, PHAM A, GORDON A, et al. Safe administration of anti-PD-1 immunotherapy in a patient with pre-existing primary biliary cholangitis[J]. Immunotherapy, 2020, 12(7): 445-450. DOI: 10.2217/imt-2019-0184. |
| [38] |
KUDO M, MATILLA A, SANTORO A, et al. Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status[J]. J Clin Oncol, 2019, 37: 327.
|
| [39] |
LEE PC, CHAO Y, CHEN MH, et al. Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. Cancers (Basel), 2020, 12(1): 182. DOI: 10.3390/cancers12010182. |
DownLoad: